Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Biochem Pharmacol ; 70(10): 1497-505, 2005 Nov 15.
Article in English | MEDLINE | ID: mdl-16188240

ABSTRACT

Macrophage migration inhibitory factor (MIF) plays some pivotal roles in innate immunity and inflammation. Ursolic acid (UA), an anti-inflammatory triterpene carboxylic acid, was recently reported to induce the release of pro-inflammatory mediators in resting macrophages (Mvarphi). We investigated the effects of UA on MIF protein release in resting RAW264.7 mouse Mvarphi, and found that it decreased intracellular MIF protein levels and promoted the release of MIF into the culture media in dose- and time-dependent manners, without affecting mRNA levels. Further, the triterpene strikingly induced activation of mitogen-activated protein kinase kinase 1/2 (MEK1/2) and extracellular signal-regulated kinase 1/2 (ERK1/2) within 30min, whereas no phosphorylation of p38 MAPK or JNK protein was observed. In addition, UA-promoted MIF release was significantly inhibited by PD98059, a MEK1/2 inhibitor, while siRNA for ERK2, but not ERK1, significantly decreased the amount of MIF protein released. These results suggest that UA triggers the release of intracellular MIF protein through the ERK2 activation.


Subject(s)
Macrophage Migration-Inhibitory Factors/metabolism , Macrophages/metabolism , Mitogen-Activated Protein Kinase 1/metabolism , Triterpenes/pharmacology , Animals , Blotting, Western/methods , Cell Line , Cell Membrane/drug effects , Cell Membrane/physiology , Cell Survival/drug effects , Cell Survival/physiology , Dose-Response Relationship, Drug , Gene Expression/drug effects , Gene Expression/genetics , MAP Kinase Kinase Kinase 1/drug effects , MAP Kinase Kinase Kinase 1/metabolism , Macrophages/drug effects , Mice , Mitogen-Activated Protein Kinase 1/drug effects , Mitogen-Activated Protein Kinase 3/drug effects , Mitogen-Activated Protein Kinase 3/metabolism , Phosphorylation , RNA, Messenger/genetics , RNA, Small Interfering/drug effects , RNA, Small Interfering/genetics , Reverse Transcriptase Polymerase Chain Reaction/methods , Time Factors , Ursolic Acid
2.
Planta Med ; 71(4): 338-43, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15856410

ABSTRACT

Propionibacterium acnes, an anaerobic pathogen, plays an important role in the pathogenesis of acne and seems to initiate the inflammatory process by producing proinflammatory cytokines. In order to demonstrate the anti-inflammatory effects and action mechanisms of magnolol and honokiol, several methods were employed. Through DPPH and SOD activity assays, we found that although both magnolol and honokiol have antioxidant activities, honokiol has relatively stronger antioxidant activities than magnolol {[for DPPH assay, % of DPPH bleaching of magnolol and honokiol (500 microM magnolol: 19.8%; 500 microM honokiol: 67.3%)]; [for SOD assay, SOD activity (200 microM magnolol: 53.4%; 200 microM honokiol: 64.3%)]}. Moreover, the production of interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNF-alpha) induced by P. acnes in THP-1 cells, a human monocytic cell line, was reduced by magnolol and honokiol {[for IL-8 (10 microM magnolol: 42.7% inhibition; 10 microM honokiol: 51.4% inhibition)]; [for TNF-alpha (10 microM magnolol: 20.3% inhibition; 10 microM honokiol: 39.0% inhibition)]}. Cyclooxygenase-2 (Cox-2) activity was also suppressed by them [(15 microM magnolol: 45.8% inhibition), (15 microM honokiol: 66.3% inhibition)]. Using a nuclear factor-kappaB (NF-kappaB) luciferase reporter assay system and Western analysis, we identified that magnolol and honokiol exert their anti-inflammatory effects by inhibiting the NF-kappaB element, which exists in Cox-2, IL-8, and TNF-alpha promoters [(15 microM magnolol: 44.8% inhibition), (15 microM honokiol: 42.3% inhibition)]. Of particular note is that magnolol and honokiol operate downstream of the MEKK-1 molecule. Together with their previously known antibacterial activity against P. acnes and based on these results, we suggest that magnolol and honokiol may be introduced as possible acne-mitigating agents.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Biphenyl Compounds/pharmacology , Lignans/pharmacology , MAP Kinase Kinase Kinase 1/drug effects , Magnolia , NF-kappa B/drug effects , Phytotherapy , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antioxidants/administration & dosage , Antioxidants/pharmacology , Antioxidants/therapeutic use , Biphenyl Compounds/administration & dosage , Biphenyl Compounds/therapeutic use , Cytokines/drug effects , Cytokines/metabolism , Humans , Interleukin-8/metabolism , Lignans/administration & dosage , Lignans/therapeutic use , Microbial Sensitivity Tests , Monocytes/drug effects , Monocytes/metabolism , Picrates/chemistry , Plant Extracts/administration & dosage , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Propionibacterium acnes/drug effects , Superoxide Dismutase/chemistry , Tumor Necrosis Factor-alpha/drug effects , Tumor Necrosis Factor-alpha/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...